Covalent inhibitor targets KRas^G12C: A new paradigm for drugging the undruggable and challenges ahead

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS is a frequently mutated oncogene in various cancers, posing therapeutic challenges.
• KRAS G12C is a specific mutation successfully targeted by recent covalent inhibitors.
• AMG510 (sotorasib) is approved for KRAS G12C-mutated non-small cell lung cancer.

Purpose of the Study:

• To review recent advancements in covalent KRAS G12C inhibitors.
• To focus on identifying predictive and monitoring biomarkers for efficacy.
• To propose rational drug combinations based on resistance mechanisms.

Main Methods:

• Literature review of preclinical and clinical studies on KRAS G12C inhibitors.
• Analysis of mechanisms underlying adaptive resistance to KRAS G12C inhibitors.
• Synthesis of data on biomarker discovery and combinatorial strategies.

Main Results:

• KRAS G12C inhibitors demonstrate efficacy in some cancers, with response rates around 50% in non-small cell lung cancer.
• Efficacy appears less favorable in colorectal and appendiceal cancers.
• Adaptive resistance is an inevitable challenge with persistent treatment.
• Combinatorial regimens are being explored to enhance efficacy.

Conclusions:

• Biomarker identification is crucial for patient stratification and predicting response to KRAS G12C inhibitors.
• Understanding resistance mechanisms is key to developing effective combination therapies.
• Further research is needed to optimize KRAS G12C inhibitor treatment strategies.